Opus Genetics (IRD) Cash from Operations (2010 - 2026)
Opus Genetics' (IRD) quarterly Cash from Operations came in at 12727000.0 in Q1 2026, down 41.51% year-on-year from 21757581.83 in Q1 2025, and down 29.43% on a QoQ basis from 9833000.0 in Q4 2025.
Opus Genetics (IRD) Cash from Operations (2010 - 2026) Analysis & Trends
Opus Genetics (IRD) has 17 years of Cash from Operations data on file, last reported at 12727000.0 in Q1 2026.
- On a quarterly basis, Cash from Operations fell 41.51% year-over-year to 12727000.0 in Q1 2026; TTM through Mar 2026 was 38986000.0, a 35.11% decrease from a year earlier, with the FY2025 full-year figure at 35253000.0, down 37.84% from the prior year.
- Cash from Operations for Q1 2026 stood at 12727000.0, down from 9833000.0 in the prior quarter.
- Over the last five years, Cash from Operations for IRD reached as high as 28791000.0 in Q4 2022 and fell as low as 12727000.0 in Q1 2026.
- Historically, Cash from Operations has averaged 3550235.29 across 5 years, with a median of 5716000.0 in 2024.
- Across the five-year window, Cash from Operations jumped 609.94% in 2022 and tumbled 837.31% in 2024, its largest moves.
- Year by year, Cash from Operations stood at 28791000.0 in 2022, then sank by 84.2% to 4548000.0 in 2023, then slumped by 263.54% to 7438000.0 in 2024, then plunged by 32.2% to 9833000.0 in 2025, then dropped by 29.43% to 12727000.0 in 2026.
- Per Business Quant data, the three most recent Cash from Operations figures were 12727000.0 in Q1 2026, 9833000.0 in Q4 2025, and 6157000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 201.34 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.17 Mn |
| 10 | Opus Genetics | 3.27 Mn | -56.73 Mn | - | -12.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -12.73 Mn |
| Mar 31, 2026 | -12.73 Mn |
| Dec 31, 2025 | -9.83 Mn |
| Dec 31, 2025 | -9.83 Mn |
| Sep 30, 2025 | -6.16 Mn |
| Sep 30, 2025 | -6.16 Mn |
| Jun 30, 2025 | -10.27 Mn |
| Jun 30, 2025 | -10.27 Mn |
| Mar 31, 2025 | -8.99 Mn |
| Mar 31, 2025 | -8.99 Mn |
| Dec 31, 2024 | -7.44 Mn |
| Dec 31, 2024 | -7.44 Mn |
| Sep 30, 2024 | -5.13 Mn |
| Sep 30, 2024 | -5.13 Mn |
| Jun 30, 2024 | -7.29 Mn |
| Jun 30, 2024 | -7.29 Mn |
| Mar 31, 2024 | -5.72 Mn |
| Mar 31, 2024 | -5.72 Mn |
| Dec 31, 2023 | 4.55 Mn |
| Dec 31, 2023 | 4.55 Mn |